Chargement en cours...
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
Abstract Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for induction therapy of AML. When used in fractionated doses, GO combined with the conventional cytarabine/anthracycline-bas...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMC
2019-10-01
|
| Collection: | Biomarker Research |
| Sujets: | |
| Accès en ligne: | http://link.springer.com/article/10.1186/s40364-019-0175-x |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Chargement en cours...